Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.
Commentary|Videos|June 16, 2024
Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL
Author(s)Sujith Samarasinghe, MD
Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.
Advertisement
Sujith Samarasinghe, MD, consultant pediatric hematologist, Great Ormond St. Hospital, discusses key results from the phase 2 ALLTOGETHER 1 DS trial evaluating the use of first-line blinatumomab (Blincyto) as chemotherapy replacement for patients with Down Syndrome B-cell acute lymphoblastic leukemia (B-ALL) that were presented at the
Advertisement
Related to this article
Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.
A rituximab biosimilar has been approved by the FDA.
Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.
Shorter treatments of venetoclax plus azacitidine did not meet similarity criteria for longer treatments in Beat acute myeloid leukemia.
A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.
Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.
The FDA has granted orphan drug designation to enzomenib for acute lymphoblastic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
4
Docirbrutinib Yields High Response Rates in MCL and CLL
5